DEVON, Pa., March 05, 2018 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced the results of a positive meeting held with the U.S. Food and Drug Administration (FDA) regarding its planned development strategy for ZYN002 in Fragile X syndrome (FXS). FXS is a rare genetic developmental disability that is the leading known cause of both inherited intellectual disability and autism spectrum disorder.
ZYN002 is the first and only pharmaceutically-produced cannabidiol (CBD) formulated as a patent-protected permeation-enhanced transdermal gel. Zynerba has received U.S. Orphan Drug designation for the use of CBD as a treatment of FXS. Currently, there are no approved therapies to treat FXS or its most common symptoms.
Based on the
... read more at: https://globenewswire.com/news-release/2018/03/05/1414690/0/en/Zynerba-Pharmaceuticals-Announces-Positive-Meeting-with-U-S-Food-and-Drug-Administration-and-Plans-to-Conduct-a-Single-Pivotal-Study-of-ZYN002-in-Fragile-X-Syndrome-to-Support-an-N.html